Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mevacor, Ditropan Switch Discussions With FDA Proceeding Well – J&J

This article was originally published in The Tan Sheet

Executive Summary

Discussions between FDA and J&J/Merck over the potential Rx-to-OTC switch of cholesterol-reducing statin Mevacor have been moving in a positive direction, J&J Consumer Pharmaceuticals & Nutritional Products Worldwide Chairman Brian Perkins reported
Advertisement

Related Content

J&J Increases European Consumer Stake With Merck Buyout
J&J Increases European Consumer Stake With Merck Buyout
J&J’s Aciphex Prescriptions May Be Feeling Effects Of Prilosec OTC Launch
Flex-5 OTC switch candidate?
Claritin, Alavert, Advil Allergy Sinus Head Major OTC Approvals In 2002
McNeil Manufacturing Changes Will Bring “Major Upgrade” To OTC Brands
Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions
Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions
Pravachol OTC Label Studies, Redefined Population Urged By Cmte.
Flexeril Indications Self-Diagnosis Seen As Significant Hurdle By Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS094593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel